Core Insights - PTC Therapeutics reported strong financial results for the fourth quarter and full year 2025, with product and royalty revenue of $831 million, exceeding guidance [1] - The global launch of Sephience™ has been successful, with significant uptake and revenue generation [1] - The company is approaching cash flow breakeven and has a robust financial position with $1.95 billion in cash as of December 31, 2025 [1] Corporate Highlights - Sephience has a strong start, with plans to expand its global footprint to 20-30 countries by the end of 2026 [1] - The company received 1,134 patient start forms in the US and has 946 patients on commercial therapy worldwide as of December 31, 2025 [1] - The FDA has shown openness to an Accelerated Approval pathway for the votoplam Huntington's disease program, with a global Phase 3 trial planned to initiate in 1H 2026 [1] Financial Highlights - Cash, cash equivalents, and marketable securities increased to $1,945.4 million from $1,139.7 million year-over-year [1] - Net income for full year 2025 was $682.6 million, a significant improvement from a net loss of $363.3 million in 2024 [1] - Total revenues for full year 2025 reached $1,730.7 million, compared to $806.8 million in 2024, driven by collaboration and license revenue of $998.4 million related to the votoplam agreement with Novartis [1][2] Revenue Breakdown - Total net product revenues for Q4 2025 were $184.0 million, compared to $150.1 million in Q4 2024 [2] - Emflaza® net product revenues decreased to $27.1 million in Q4 2025 from $50.5 million in Q4 2024 [1] - Translarna™ net product revenues also declined to $39.0 million in Q4 2025 from $89.1 million in Q4 2024 [1] 2026 Financial Guidance - The company projects non-GAAP R&D and SG&A expenses of $680 to $720 million for 2026, excluding estimated non-cash, stock-based compensation expense of $95 million [1] - Total product revenue is expected to be between $700 to $800 million, representing a 19% to 36% increase from 2025, primarily driven by Sephience [1]

Core Viewpoint - PTC Therapeutics has received marketing authorization from the European Commission for Sephience™ (sepiapterin) to treat phenylketonuria (PKU) in patients of all ages and disease severities, marking a significant advancement in treatment options for this rare metabolic disorder [1][2][3] Group 1: Product Information - Sephience™ (sepiapterin) is indicated for the treatment of hyperphenylalaninaemia (HPA) in both adult and pediatric patients with PKU, acting as a natural precursor of the enzymatic co-factor BH4, which is essential for the enzyme phenylalanine hydroxylase (PAH) [4] - The product functions as a dual pharmacological chaperone, improving the activity of defective PAH enzymes and effectively reducing blood phenylalanine (Phe) levels [4] - The European launch of Sephience will begin in Germany in the first half of July 2025, with ongoing review for approval in other countries including Japan and Brazil [3] Group 2: Clinical Evidence - The European approval is based on statistically significant results from the Phase 3 APHENITY trial, demonstrating a durable treatment effect and allowing participants to liberalize their diet in the long-term extension study [2] Group 3: Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders, leveraging scientific expertise and a global commercial infrastructure to maximize value for patients [6] - The company aims to provide access to best-in-class treatments for patients with unmet medical needs, supported by a robust and diversified pipeline of transformative medicines [6]

Core Insights - PTC Therapeutics reported strong revenue performance of $190 million for the first quarter of 2025, with a significant cash position exceeding $2 billion as of March 31, 2025, supporting ongoing commercial and R&D activities [1][8]. Financial Performance - Total net product and royalty revenue for Q1 2025 was $190 million, a decrease from $208.8 million in Q1 2024 [5]. - Revenue from the DMD franchise was $134 million, with Translarna™ contributing $86 million and Emflaza® contributing $48 million [5]. - Collaboration and license revenue included $986.2 million from the PTC518 agreement with Novartis, which closed in January 2025 [5][7]. - Net income for Q1 2025 was $866.6 million, compared to a net loss of $91.6 million in Q1 2024 [8]. Regulatory and Clinical Updates - Positive CHMP opinion for Sephience™ (sepiapterin) received on April 25, 2025, with an expected European Commission adoption in approximately two months [5]. - NDA for Sephience is under review by the FDA, with a target action date of July 29, 2025 [5]. - NDA for vatiquinone accepted and granted Priority Review by the FDA, with a target action date of August 19, 2025 [5]. - Phase 2 PIVOT-HD study for PTC518 met primary endpoint of dose-dependent blood HTT lowering at Week 12, with favorable safety and tolerability [5]. Guidance and Future Outlook - PTC anticipates full-year 2025 revenue between $650 million and $800 million, including in-line products and potential new launches [8]. - Full-year 2025 GAAP R&D and SG&A expenses are projected to be between $805 million and $835 million [8]. - Non-GAAP R&D and SG&A expenses are expected to be between $730 million and $760 million, excluding estimated non-cash, stock-based compensation of $75 million [8].

Core Viewpoint - PTC Therapeutics has received a positive opinion from the CHMP of the EMA for the marketing authorization of Sephience™ (sepiapterin) to treat phenylketonuria (PKU), addressing a significant unmet medical need in Europe [1][2]. Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on developing and commercializing medicines for rare disorders, with a robust pipeline of transformative therapies [7]. Product Information - Sephience is an oral formulation of synthetic sepiapterin that acts through a dual mechanism to enhance the activity of the phenylalanine hydroxylase (PAH) enzyme, effectively reducing blood phenylalanine levels [5]. - The product is designed to cater to a broad range of PKU patients, including those with severe disease subtypes [2][5]. Regulatory Developments - The European Commission is expected to ratify the marketing authorization for Sephience in approximately two months, which will apply to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein [3]. - The New Drug Application (NDA) for sepiapterin is currently under review by the U.S. FDA, with a target action date of July 29, 2025 [4]. Market Launch Plans - PTC is preparing for the European launch of Sephience, with initial focus on Germany and other key markets where named patient access will be available immediately following the positive opinion [2][8]. Disease Context - Phenylketonuria (PKU) is a rare inherited metabolic disorder affecting approximately 58,000 people globally, characterized by the inability to break down phenylalanine, leading to severe neurological damage if untreated [6].

Core Viewpoint - PTC Therapeutics has received a positive opinion from the CHMP of the EMA for the marketing authorization of Sephience™ (sepiapterin) to treat phenylketonuria (PKU), addressing a significant unmet medical need in Europe [1][2]. Company Overview - PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing, and commercializing differentiated medicines for rare disorders [7]. Product Information - Sephience is an oral formulation of synthetic sepiapterin that acts through a dual mechanism to enhance the activity of the phenylalanine hydroxylase (PAH) enzyme, effectively reducing blood phenylalanine levels [5]. - The product is designed to treat a broad range of PKU patients, including those with severe disease subtypes [5]. Regulatory Developments - The European Commission is expected to ratify the marketing authorization for Sephience in approximately two months, which will apply to all 27 EU member states, as well as Iceland, Norway, and Liechtenstein [3]. - The New Drug Application (NDA) for sepiapterin is currently under review by the U.S. FDA, with a target action date of July 29, 2025 [4]. Market Potential - There are an estimated 58,000 people living with PKU globally, indicating a significant market opportunity for Sephience [6]. - Launch preparations for Sephience are underway, with a focus on Germany and other key European markets [2].